Description
PD-325901isananticancerchemotherapeuticMEK1/2andRafinhibitorthatisparticularlyeffectiveagainstcancersharboringB-RaforRasmutationssuchasV600E.PD-325901decreaseslevelsofphosphorylatedERK1/2,cyclinD1,andthymidinekinase1.PD-325901alsoinducescellcyclearrestattheG0/G1phase,inhibitingproliferationinthyroidcancercelllines.Invivo,thiscompounddecreasestumorgrowthandsize.Additionally,PD-325901displaysantiviralbenefit,synergizingwithothertreatmentsincellularmodelsofinfluenzainfection.
References
HaasbachE,HartmayerC,PlanzO.CombinationofMEKinhibitorsandoseltamivirleadstosynergisticantiviraleffectsafterinfluenzaAvirusinfectioninvitro.AntiviralRes.2013May;98(2):319-24.PMID:23523553.
LeytonJ,SmithG,LeesM,etal.NoninvasiveimagingofcellproliferationfollowingmitogenicextracellularkinaseinhibitionbyPD0325901.MolCancerTher.2008Sep;7(9):3112-21.PMID:18790789.
LiuD,XingM.PotentinhibitionofthyroidcancercellsbytheMEKinhibitorPD0325901anditspotentiationbysuppressionofthePI3KandNF-kappaBpathways.Thyroid.2008Aug;18(8):853-64.PMID:18651802.
BrownAP,CarlsonTC,LoiCM,etal.PharmacodynamicandtoxicokineticevaluationofthenovelMEKinhibitor,PD0325901,intheratfollowingoralandintravenousadmiNISTration.CancerChemotherPharmacol.2007Apr;59(5):671-9.PMID:16944149.